1. Associations of Adverse Clinical Course and Ingested Substances among Patients with Deliberate Drug Poisoning: A Cohort Study from an Intensive Care Unit in Japan;Ichikura;PLoS One.,2016
2. Okumura Y, Sakata N, Takahashi K, Nishi D, Tachimori H. Epidemiology of overdose episodes from the period prior to hospitalization for drug poisoning until discharge in Japan: An exploratory descriptive study using a nationwide claims database. J Epidemiol. 2017 Aug;27(8):373-380. 10.1016/j.je.2016.08.010. Epub 2017 Feb 24. PMID: 28242045; PMCID: PMC5549249.
3. Landry I, Aluri J, Nakai K, Hall N, Miyajima Y, Ueno T, Dayal S, Filippov G, Lalovic B, Moline M, Reyderman L. Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant. Clin Pharmacol Drug Dev. 2021 Jun;10(6):681-690. 10.1002/cpdd.915. Epub 2021 Jan 17. PMID: 33455055; PMCID: PMC8248323.
4. U.S. Food and Drug Administration. DAYVIGO (lemborexant): Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf, 2024(accessed 1 July 2024).
5. Eisai Co., Ltd. DAYVIGO (lemborexant): Prescribing information. https://medical2.eisai.jp/fileviewer/5tjaftxsj1/, 2024(accessed 1 July 2024).